PREDICTORS OF NO-REFLOW PHENOMENON AFTER PCI IN PAKISTANI PATIENTS

WA KHAN; HR VISHNO; SA SHAIKH; A MEMON; R KHAN

doi:10.54112/bcsrj.v2024i1.1000

Authors

WA KHAN Department of Cardiology, Army Cardiac Center, CMH Lahore, Pakistan
HR VISHNO Department of Cardiology, National Institute of Cardiovascular Diseases Karachi, Pakistan
SA SHAIKH Department of Cardiology, National Institute of Cardiovascular Diseases Karachi, Pakistan
A MEMON Department of Cardiology, National Institute of Cardiovascular Diseases Karachi, Pakistan
R KHAN Department Cardiology, Fazaia Ruth PFAU, Medical College (FRPMC), Karachi, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2024i1.1000

Keywords:

No-reflow phenomenon,, percutaneous coronary intervention, , diabetes mellitus, , hypertension, , left ventricular ejection fraction, , Pakistan, , myocardial infarction,

Abstract

The no-reflow phenomenon is a perplexing complication of PCI. It is marked by poor coronary microvascular perfusion despite successful revascularization. This condition can lead to adverse outcomes such as myocardial infarction and heart failure. Various treatments exist, including pharmacological agents and mechanical interventions, but no flow remains a significant clinical challenge. Objective: This study aims to identify predictors of the no-reflow phenomenon in Pakistani patients undergoing PCI. Methods: Conducted at the National Institute of Cardiovascular Diseases (NICVD) in Karachi from January 2020 to December 2021, this observational study included 256 patients undergoing primary PCI for acute myocardial infarction. Baseline characteristics such as age, sex, BMI, diabetes status, hypertension, smoking status, and left ventricular ejection fraction (LVEF) were recorded. The primary outcome was the incidence of no-reflow, with secondary outcomes including in-hospital mortality and heart failure. Data analysis was performed using SPSS software, with logistic regression pinpointing independent predictors of no-reflow. Results: The patients had a mean age of 58.4 ± 12.3 years, and the median was 59 years. Most patients were male (78.1%). Significant predictors of no-reflow included diabetes mellitus (OR: 2.1, 95% CI: 1.2-3.7, p=0.01), hypertension (OR: 1.8, 95% CI: 1.0-3.2, p=0.04), and reduced LVEF (OR: 1.5 per 5% decrease, 95% CI: 1.2-2.1, p<0.001). Patients experiencing no-reflow had higher in-hospital mortality (11.1% vs. 4.0%, p<0.05) and heart failure rates (24.1% vs. 10.4%, p<0.01) compared to those with normal flow. Conclusion: Diabetes mellitus, hypertension, and reduced LVEF are significant predictors of the no-reflow phenomenon in Pakistani patients undergoing PCI. Identifying high-risk patients allows for targeted preventative strategies to improve clinical outcomes.

Downloads

Download data is not yet available.

References

Dangas GD, Caixeta A, Mehran R, Parise H, Lansky AJ, Cristea E, et al. Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction. Circulation. 2011;123(16):1745-56.

Harrison RW, Aggarwal A, Ou F-s, Klein LW, Rumsfeld JS, Roe MT, et al. Incidence and outcomes of no-reflow phenomenon during percutaneous coronary intervention among patients with acute myocardial infarction. The American journal of cardiology. 2013;111(2):178-84.

Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation. 2002;105(5):656-62.

Morishima I, Sone T, Mokuno S, Taga S, Shimauchi A, Oki Y, et al. Clinical significance of no-reflow phenomenon observed on angiography after successful treatment of acute myocardial infarction with percutaneous transluminal coronary angioplasty. American heart journal. 1995;130(2):239-43.

Zhao Y, Chen Y, Tian F, Wang C, Hu S, Wang J, et al. Predictors of the no-reflow phenomenon after primary percutaneous coronary intervention for acute myocardial infarction. Nan fang yi ke da xue xue bao= Journal of Southern Medical University. 2012;32(2):261-4.

Niccoli G, Burzotta F, Galiuto L, Crea F. Myocardial no-reflow in humans. Journal of the American College of Cardiology. 2009;54(4):281-92.

Baran KW, Nguyen M, McKendall GR, Lambrew CT, Dykstra G, Palmeri ST, et al. Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction: limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study. Circulation. 2001;104(23):2778-83.

Jaffe R, Dick A, Strauss BH. Prevention and treatment of microvascular obstruction-related myocardial injury and coronary no-reflow following percutaneous coronary intervention: a systematic approach. JACC: Cardiovascular Interventions. 2010;3(7):695-704.

De Luca G, Van't Hof AW, Ottervanger JP, Hoorntje JC, Gosselink AM, Dambrink J-HE, et al. Ageing, impaired myocardial perfusion, and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty. European heart journal. 2005;26(7):662-6.

Ndrepepa G, Mehilli J, Schulz S, Iijima R, Keta D, Byrne RA, et al. Prognostic significance of epicardial blood flow before and after percutaneous coronary intervention in patients with acute coronary syndromes. Journal of the American College of Cardiology. 2008;52(7):512-7.

Oikonomou EK, Thangaraj PM, Bhatt DL, Ross JS, Young LH, Krumholz HM, et al. An explainable machine learning-based phenomapping strategy for adaptive predictive enrichment in randomized clinical trials. NPJ digital medicine. 2023;6(1):217.

Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, et al. Strategies for multivessel revascularization in patients with diabetes. New England journal of medicine. 2012;367(25):2375-84.

Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. New England Journal of Medicine. 2006;354(16):1685-97.

Gheorghiade M, Pang PS. Acute heart failure syndromes. Journal of the American College of Cardiology. 2009;53(7):557-73.

Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine. 2007;357(20):2001-15.

T O'Gara P, Kushner FG, Ascheim DD, Casey DE, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary. Journal of the American College of Cardiology. 2013;61(4):485.